DETROIT, Dec. 8 /PRNewswire/ -- Pivotal Research Centers has begun accepting candidates for a research study to evaluate an investigational medication for persistent gastrointestinal (GI) dysfunction in autistic children. Pivotal Research Centers is one of only 12 sites in the nation to be selected to participate in this medical study.
The study aims to determine the impact on GI function through treatment as well as assess the effect of GI symptoms on physical or emotional behavior.
To be considered for participation in the study, a child must be between 2 and 17 years of age; be diagnosed with autism, and experience some of the following symptoms:
* Chronic diarrhea or constipation * Bloating * Gas * Abdominal pain
Research volunteers will receive study medication and medical care at no cost to the family.
“With as many as 50 percent of children with autistic disorder experiencing regular GI problems, we recognize the significant impact these issues have on the autism community, which currently has limited information on the cause and appropriate treatments,” says Richard Jackson, M.D., Principal Investigator, Pivotal Research Centers.
Autism is the most common of the Pervasive Developmental Disorders, affecting an estimated 1 in 250 births (Centers for Disease Control and Prevention, 2003). This means that as many as 1.5 million Americans today are believed to have some form of autism.(1)
To find out more about the study as well as additional inclusion/exclusion criteria, please contact Pivotal Research Centers at 1-866-STUDY 21.
(1) Autism Society of America
(http://www.autism-society.org/site/PageServer?pagename-whatisautisin)
Pivotal Research Centers
CONTACT: Pivotal Research Centers, 1-866-STUDY 21,studies@pivotalresearch.com
